Develops blood purification therapies to treat life-threatening conditions in critically ill patients.
Cytosorbents Corporation, headquartered in Princeton, New Jersey, is a pioneering company dedicated to researching, developing, and commercializing medical devices utilizing its proprietary blood purification technology platform. At the core of its innovative solutions is a unique adsorbent and porous polymer technology, designed to enhance patient care across various critical care and medical applications.
The company's flagship product, CytoSorb, serves as an extracorporeal cytokine filter used in adjunctive therapy for treating sepsis and other critical care conditions. It also plays a crucial role in preventing perioperative complications during cardiopulmonary bypass surgery and optimizing the quality of solid organs for transplantation. Cytosorbents Corporation expands its impact through VetResQ, tailored for veterinary applications, and CytoSorb-XL, an enhanced version for broader therapeutic use in sepsis and critical illnesses.
Additionally, Cytosorbents develops advanced technologies like HemoDefend to purify blood by reducing contaminants that can lead to transfusion reactions. Other innovations include K+ontrol for managing severe hyperkalemia, ContrastSorb for mitigating the risk of contrast-induced nephropathy during imaging procedures, and ongoing projects such as BetaSorb for chronic renal failure and DrugSorb for removing toxic chemicals from the blood. Established in 1997 as MedaSorb Technologies Corporation and rebranded as Cytosorbents Corporation in 2010, the company continues to lead the industry with its commitment to advancing life-saving medical solutions worldwide.